Microwave ablation therapy for treating primary and secondary lung tumours: technical note

Carrafiello, Gianpaolo; Mangini, Monica; Bernardi, Irene De; Fontana, Federico; Dionigi, Gianlorenzo; Cuffari, Salvatore; Imperatori, Andrea; Laganà, Domenico; Fugazzola, Carlo

doi:10.1007/s11547-010-0547-7

Cited by 23 publications

(15 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most common complication after percutaneous PMCT treatment was pneumothorax caused by pulmonary needle biopsy, and the incidence rate of pneumothorax was about 15% to 45% [22,24,26,27]. In our study, the incidence rate of pneumothorax was 18.84%.…”

Section: Discussionmentioning

confidence: 48%

CT-guided percutaneous microwave ablation of pulmonary malignancies: Results in 69 cases

et al. 2012

View full text Add to dashboard Cite

BackgroundMicrowave ablation (MWA) has attracted a worldwide attention gradually in treating inoperable pulmonary malignancies. However, in the lung tissues treated with MWA recurrence of tumor may still occur and few data in large patient groups till now were reported about the safety or effectiveness of microwave ablation in treating primary lung cancer and metastatic pulmonary malignancies. The purpose of this study is to evaluate the clinical curative effect (local control, survival data) MWA and its safety as well.MethodsFrom 1 January 2005 to 1 January 2008, retrospective analyses, 69 patients underwent computed tomography (CT)-guided percutaneous MWA of pulmonary malignancies. All patients were deemed medically inoperable. The correlation of tumor sizes and local progression after ablation was analyzed and the survival rates within 3 years post surgery were compared between non-small-cell lung cancer and pulmonary metastases groups also.ResultsPneumothorax was the most frequent complication and occurred in 24.64% patients after ablation. Neither needle track implantation was found nor did patient death occur in these patients within 30 days. The 1-, 2-, and 3-year overall survival rates were 66.7%, 44.9% and 24.6%, respectively. The overall survival rates for NSCLC patients in 1 year, 2 years, and 3 years were 75.0%, 54.2%, and 29.2%, respectively. The overall survival rates for pulmonary metastatic tumor patients in 1 year, 2 years, and 3 years were 47.6%, 23.8%, and 14.3%, respectively. The recurrence-free survival rates for NSCLC patients in 1 year, 2 years, and 3 years were 72.9%, 50.0%, and 27.1%, respectively. The mortality rates for pulmonary metastatic tumor patients in 1 year, 2 years, and 3 years were 47.6%, 19.0%, and 14.3%, respectively.ConclusionsPercutaneous microwave coagulation therapy was one safe and effective method and could be beneficial for the improvement of inoperable pulmonary malignancies treatment effect.

show abstract

Section: Discussionmentioning

confidence: 48%

CT-guided percutaneous microwave ablation of pulmonary malignancies: Results in 69 cases

et al. 2012

View full text Add to dashboard Cite

show abstract

“…CBCT may provide a guidance method for ablation procedures and enables ablation procedures requiring CT guidance to be performed in the interventional fluoroscopy/angiography suite, without requiring a CT and without impacting workflow, especially in facilities without a dedicated IR CT [60]. …”

Section: Clinical Applicationsmentioning

confidence: 99%

C-arm cone-beam computed tomography in interventional oncology: technical aspects and clinical applications

et al. 2014

View full text Add to dashboard Cite

C-arm cone-beam computed tomography (CBCT) is a new imaging technology integrated in modern angiographic systems. Due to its ability to obtain cross-sectional imaging and the possibility to use dedicated planning and navigation software, it provides an informed platform for interventional oncology procedures. In this paper, we highlight the technical aspects and clinical applications of CBCT imaging and navigation in the most common loco-regional oncological treatments.

show abstract

“…In the study of He et al (2007) on MWA treatment for peripheral lung cancer, 17 patients with a total of 23 tumor nodules were followed up for 6 to 47 months (mean 23 months); therein, the lesions were shown to have shrunk to different degrees with disappear-ance or reduction of the internal flow signal after treatment; enhanced CT revealed that 13 tumor nodules had no enhancement, while the other seven received partial enhancement; after treatment, tumors reached complete necrosis in the ablation area in four patients; one month after MWA, clinical symptoms disappeared in nine patients, and eased in nine. Carrafiello et al (2010) recommended MWA to replace other ablations and to be the first choice for some patients. The further analysis of the effects on growth factors that promote tumor growth, metastasis, and recurrence after microwave treatment would have a profound meaning for the further development of MWA.…”

Section: Discussionmentioning

confidence: 99%

Effects of microwave ablation or its combination with whole-body chemotherapy on serum vascular endothelial growth factor levels in patients with stage IIIB/IV NSCLC

Sun¹,

Py²,

Guo³

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

Microwave ablation therapy for treating primary and secondary lung tumours: technical note

Cited by 23 publications

References 33 publications

CT-guided percutaneous microwave ablation of pulmonary malignancies: Results in 69 cases

CT-guided percutaneous microwave ablation of pulmonary malignancies: Results in 69 cases

C-arm cone-beam computed tomography in interventional oncology: technical aspects and clinical applications

Effects of microwave ablation or its combination with whole-body chemotherapy on serum vascular endothelial growth factor levels in patients with stage IIIB/IV NSCLC

Contact Info

Product

Resources

About